Matthew Nudy, MD, on estrogen's cardiovascular effects, risk assessment, and hormone therapy safety in younger menopausal women.
|Slideshows|August 30, 2019
Common hereditary cancer syndromes with breast and gynecologic malignancies
Author(s)Susan C. Modesitt, MD, Christine Garcia, MD
As they often serve as primary care providers, ob/gyns are uniquely positioned to help identify at-risk women before they develop cancer.
Advertisement
Advertisement
Related to this article
Samples from a large UK screening trial supported validation of the investigational Evident ovarian cancer test, according to Dawn Mattoon, PhD.
Lisa Taylor-Swanson, PhD, on a pilot in which integrative group medical visits improved menopause symptoms, knowledge, and self-efficacy.
Peter Hsin, BS, discusses a meta-analysis linking perioperative ketamine to lower early postpartum depressive symptoms after cesarean delivery.
A recap of the top video interviews from Contemporary OB/GYN's coverage of The Menopause Society 2026 Annual Meeting in San Diego.
Susan Reed, MD, MPH, MS, and Calbeth C. Alaribe, DMSc, MPH, PA-C, CPCHE, weigh in on FDA boxed warning removals for menopausal hormone therapy.
The FDA granted accelerated approval to Voceryq to reduce papilloma excision surgeries in adults with recurrent respiratory papillomatosis.
A recap of the top women's health headlines from October 2026, including FDA approval of pritelivir for refractory HSV, ACOG's new menopause guideline, and more.
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
Reactions to FDA's boxed warning removals for menopausal hormone therapy
2
Top headlines in women's health from October 2026
3
Top video interviews from The Menopause Society 2026 Annual Meeting
4
FDA grants accelerated approval to DNA immunotherapy for adult recurrent respiratory papillomatosis
5